Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease
about
Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseasesMouse models of polyglutamine diseases: review and data table. Part IMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityCalpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse modelThe Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability.SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's diseaseNeurochemical correlates of caudate atrophy in Huntington's disease.Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system.Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten diseaseDifferential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activityDifferential electrophysiological changes in striatal output neurons in Huntington's disease.Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington diseaseForebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice.Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten diseaseHuntington's Disease and Striatal Signaling.The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs).Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppressionA critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceAllosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's diseaseMultiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.The clinical and genetic features of Huntington disease.Huntington's disease: can mice lead the way to treatment?Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms.Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease
P2860
Q26830654-C838D70A-796F-40E8-8C22-F5F88237E952Q26853025-192C3B83-6C16-43CF-8000-52DEC751E8D8Q27005950-C87B9E11-D2C0-4755-AA56-D1B846E60C2AQ28239309-CBBCA373-13C3-4A98-8800-581263161A00Q28265056-31A6FA37-FD0F-4E9F-8EF8-5721C44E09F4Q28571426-ED3EF73B-793A-4C09-AD4E-0FE10F5664C0Q28741746-CBF42539-1DC2-4159-B0F8-D938BDF7C05FQ29994841-CF70A850-73D3-42FC-966C-3687D6656545Q30737232-00375FF4-C343-4F0F-9808-04099A097B7AQ33786465-31B8100E-3090-4182-9140-64D6F198764AQ34071987-268E7CF8-BC03-45C1-944A-8F16D5FB7622Q34280201-379EDE98-D23C-4A01-9DFE-A04EDCF9FC99Q34341619-D07DE60F-4C5E-4FF6-8C72-6E3FEC5C4106Q34634421-533EB7E5-59C0-4262-919D-441B2551462AQ34764514-B1BE86E1-4D14-4B5E-A8D8-EB067EF63546Q34780443-3987F41A-4B65-42E1-901A-D9B58E25C6D4Q35146890-48FF496C-20AF-42B1-B666-68804429B7AAQ35161675-631D3D3D-E1C0-4E9D-9750-821602085AB0Q35181056-56DF131A-ED3C-4A3D-92E3-7B8152FCAD10Q35216601-0B7B63EC-7911-4377-AE42-1F7D68A7B3EBQ35286098-26700D3E-48EB-469C-914E-5BA09A80087BQ35340099-930874C7-F496-41A3-95A9-377F2D5CE14BQ35560350-A91ACF76-8207-4A48-9275-882BD7A8B5C7Q35840603-314BFD18-8B47-4E36-AB86-BABFC3A96515Q35852016-4EDB05AB-BDA5-45AC-B3EF-AE0DF4137418Q35951187-1F4E5FAD-3AE9-4BCF-BED5-A137EC61A623Q36037085-91200642-A914-43F3-93C1-14707FB8294DQ36300365-0B2DE974-4908-4FBB-9034-613B664C35FCQ36931043-CDD7B19A-42F1-4714-8A4E-C688053348B5Q36940345-3A9FD57D-C9E0-4007-BED1-0C3BEFA46DE8Q36984277-54DDBA10-7FCE-4189-AAFC-640B83CC51F2Q37255018-B76D9CE8-7BA6-49D9-9B10-CF28D7A038F5Q37607024-BE926B19-40AF-47E8-A119-2BABB645B088Q37731940-F99CA5A5-8529-465E-AAB4-CA46208B646AQ37798079-1FDC1E07-7F3F-4BE7-9E2F-F3F46BAC50B2Q37840353-571B26D6-D25B-4BE1-9506-CEE3837D89B4Q37866383-C0EB2CE0-541B-46A8-9E56-F0401F2B5591Q37930190-19271A77-43D1-47A7-8F43-D2246A62DA92Q37992617-71E84243-0079-4AC8-B995-FDE7324F0F56Q37996350-C69E6666-A457-4C19-A332-C6DA036B4FB5
P2860
Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differential susceptibility to ...... ion and progression of disease
@en
Differential susceptibility to ...... on and progression of disease.
@nl
type
label
Differential susceptibility to ...... ion and progression of disease
@en
Differential susceptibility to ...... on and progression of disease.
@nl
prefLabel
Differential susceptibility to ...... ion and progression of disease
@en
Differential susceptibility to ...... on and progression of disease.
@nl
P2093
P2860
P50
P1476
Differential susceptibility to ...... ion and progression of disease
@en
P2093
Bryan E Figueroa
Elizabeth J Slow
Martina Metzler
Michael S Levine
Nan-Ping Wu
Prasad Joshi
Robert Friedlander
Rona K Graham
Véronique M André
P2860
P304
P356
10.1523/JNEUROSCI.5473-08.2009
P407
P577
2009-02-01T00:00:00Z